<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32517029</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>05</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Antiviral Activity of Compound L3 against Dengue and Zika Viruses In Vitro and In Vivo.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4050</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21114050</ELocationID><Abstract><AbstractText>Dengue virus (DENV) and Zika virus (ZIKV) are mosquito-borne flaviviruses that cause severe illness after infection. Currently, there are no specific or effective treatments against DENV and ZIKV. Previous studies have shown that tyrosine kinase activities and signal transduction are involved in flavivirus replication, suggesting a potential therapeutic strategy for DENV and ZIKV. In this study, we found that compound <b>L3</b> can significantly reduce viral protein expression and viral titers in HEK-293, MCF-7, HepG2, and Huh-7 cells and exhibits superior therapeutic efficacy against flaviviral infection compared to other tyrosine kinase inhibitors. In addition, compound <b>L3</b> can decrease endogenous HER2 activation and inhibit the phosphorylation of the HER2 downstream signaling molecules Src and ERK1/2, the levels of which have been associated with viral protein expression in MCF-7 cells. Moreover, silencing HER2 diminished DENV-2 and ZIKV expression in MCF-7 cells, which suggests that HER2 activity is involved in flavivirus replication. Furthermore, in DENV-2-infected AG129 mice, treatment with compound <b>L3</b> increased the survival rates and reduced the viremia levels. Overall, compound <b>L3</b> demonstrates therapeutic efficacy both in vitro and in vivo and could be developed as a promising antiviral drug against emerging flaviviruses or for concurrent DENV and ZIKV outbreaks.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Fu-Kai</ForeName><Initials>FK</Initials><AffiliationInfo><Affiliation>Penghu Branch of Tri-Service General Hospital, Penghu 88056, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Ching-Len</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, National Defense Medical Center, 161, Sec. 6, Min-Chuan E. Road, Neihu, Taipei 11490, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli 35053, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Ming-Kuan</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>School of Pharmacy, National Defense Medical Center, Taipei 11490, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Yi-Lin</ForeName><Initials>YL</Initials><Identifier Source="ORCID">0000-0002-1827-6924</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, National Defense Medical Center, Taipei 11490, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>An-Rong</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>School of Pharmacy, National Defense Medical Center, Taipei 11490, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Shih-Ming</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, National Defense Medical Center, Taipei 11490, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Yu-Lung</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>School of Public Health, National Defense Medical Center, Taipei 11490, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Pei-Ling</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, National Defense Medical Center, 161, Sec. 6, Min-Chuan E. Road, Neihu, Taipei 11490, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli 35053, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Bo-Cyuan</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, National Defense Medical Center, 161, Sec. 6, Min-Chuan E. Road, Neihu, Taipei 11490, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Tsung-Hsien</ForeName><Initials>TH</Initials><Identifier Source="ORCID">0000-0003-4806-7864</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, National Defense Medical Center, 161, Sec. 6, Min-Chuan E. Road, Neihu, Taipei 11490, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chang-Chi</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, National Defense Medical Center, 161, Sec. 6, Min-Chuan E. Road, Neihu, Taipei 11490, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Preventive Medicine, National Defense Medical Center, Taipei 11490, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>Chih-Chin</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, National Defense Medical Center, Taipei 11490, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yen</LastName><ForeName>Li-Chen</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0002-1891-5546</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, National Defense Medical Center, 161, Sec. 6, Min-Chuan E. Road, Neihu, Taipei 11490, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOST 105-2628-B-016-002-MY2</GrantID><Agency>Ministry of Science and Technology, Taiwan</Agency><Country/></Grant><Grant><GrantID>MAB-107-078, MAB-108-054 and MAB-109-060</GrantID><Agency>Ministry of National Defense Medical Affairs Bureau</Agency><Country/></Grant><Grant><GrantID>TSGH-PH-106-02 and TSGH-PH-107-01</GrantID><Agency>Tri-Service General Hospital</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>41UD74L59M</RegistryNumber><NameOfSubstance UI="D000077716">Afatinib</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000077716" MajorTopicYN="N">Afatinib</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071244" MajorTopicYN="N">Zika Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071243" MajorTopicYN="N">Zika Virus Infection</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Zika virus</Keyword><Keyword MajorTopicYN="N">anti-viral drugs</Keyword><Keyword MajorTopicYN="N">dengue virus</Keyword><Keyword MajorTopicYN="N">flavivirus</Keyword><Keyword MajorTopicYN="N">tyrosine kinase inhibitors</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32517029</ArticleId><ArticleId IdType="pmc">PMC7312370</ArticleId><ArticleId IdType="doi">10.3390/ijms21114050</ArticleId><ArticleId IdType="pii">ijms21114050</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neufeldt C.J., Cortese M., Acosta E.G., Bartenschlager R. Rewiring cellular networks by members of the flaviviridae family. Nat. Rev. Microbiol. 2018;16:125&#x2013;142. doi: 10.1038/nrmicro.2017.170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro.2017.170</ArticleId><ArticleId IdType="pmc">PMC7097628</ArticleId><ArticleId IdType="pubmed">29430005</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong H.Y., Leow C.Y., Abdul Majeed A.B., Leow C.H. Flavivirus infection-a review of immunopathogenesis, immunological response, and immunodiagnosis. Virus Res. 2019;274:197770. doi: 10.1016/j.virusres.2019.197770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2019.197770</ArticleId><ArticleId IdType="pubmed">31626874</ArticleId></ArticleIdList></Reference><Reference><Citation>Dos Santos Franco L., Gushi L.T., Luiz W.B., Amorim J.H. Seeking flavivirus cross-protective immunity. Front. Immunol. 2019;10:2260. doi: 10.3389/fimmu.2019.02260.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02260</ArticleId><ArticleId IdType="pmc">PMC6763598</ArticleId><ArticleId IdType="pubmed">31616432</ArticleId></ArticleIdList></Reference><Reference><Citation>Quicke K.M., Bowen J.R., Johnson E.L., McDonald C.E., Ma H., O&#x2019;Neal J.T., Rajakumar A., Wrammert J., Rimawi B.H., Pulendran B., et al. Zika virus infects human placental macrophages. Cell Host Microbe. 2016;20:83&#x2013;90. doi: 10.1016/j.chom.2016.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2016.05.015</ArticleId><ArticleId IdType="pmc">PMC5166429</ArticleId><ArticleId IdType="pubmed">27247001</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen S.A., Jamieson D.J., Honein M.A., Petersen L.R. Zika virus and birth defects--reviewing the evidence for causality. N. Engl. J. Med. 2016;374:1981&#x2013;1987. doi: 10.1056/NEJMsr1604338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsr1604338</ArticleId><ArticleId IdType="pubmed">27074377</ArticleId></ArticleIdList></Reference><Reference><Citation>Manet C., Roth C., Tawfik A., Cantaert T., Sakuntabhai A., Montagutelli X. Host genetic control of mosquito-borne flavivirus infections. Mamm. Genome Off. J. Int. Mamm. Genome Soc. 2018;29:384&#x2013;407. doi: 10.1007/s00335-018-9775-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00335-018-9775-2</ArticleId><ArticleId IdType="pubmed">30167843</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Garcia M.D., Mazzon M., Jacobs M., Amara A. Pathogenesis of flavivirus infections: Using and abusing the host cell. Cell Host Microbe. 2009;5:318&#x2013;328. doi: 10.1016/j.chom.2009.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2009.04.001</ArticleId><ArticleId IdType="pubmed">19380111</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith J.L., Stein D.A., Shum D., Fischer M.A., Radu C., Bhinder B., Djaballah H., Nelson J.A., Fruh K., Hirsch A.J. Inhibition of dengue virus replication by a class of small-molecule compounds that antagonize dopamine receptor d4 and downstream mitogen-activated protein kinase signaling. J. Virol. 2014;88:5533&#x2013;5542. doi: 10.1128/JVI.00365-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00365-14</ArticleId><ArticleId IdType="pmc">PMC4019099</ArticleId><ArticleId IdType="pubmed">24599995</ArticleId></ArticleIdList></Reference><Reference><Citation>Meertens L., Carnec X., Lecoin M.P., Ramdasi R., Guivel-Benhassine F., Lew E., Lemke G., Schwartz O., Amara A. The tim and tam families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe. 2012;12:544&#x2013;557. doi: 10.1016/j.chom.2012.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2012.08.009</ArticleId><ArticleId IdType="pmc">PMC3572209</ArticleId><ArticleId IdType="pubmed">23084921</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar R., Agrawal T., Khan N.A., Nakayama Y., Medigeshi G.R. Identification and characterization of the role of c-terminal src kinase in dengue virus replication. Sci. Rep. 2016;6:30490. doi: 10.1038/srep30490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep30490</ArticleId><ArticleId IdType="pmc">PMC4960526</ArticleId><ArticleId IdType="pubmed">27457684</ArticleId></ArticleIdList></Reference><Reference><Citation>De Wispelaere M., LaCroix A.J., Yang P.L. The small molecules azd0530 and dasatinib inhibit dengue virus rna replication via fyn kinase. J. Virol. 2013;87:7367&#x2013;7381. doi: 10.1128/JVI.00632-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00632-13</ArticleId><ArticleId IdType="pmc">PMC3700292</ArticleId><ArticleId IdType="pubmed">23616652</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakaria M.K., Carletti T., Marcello A. Cellular targets for the treatment of flavivirus infections. Front. Cell. Infect. Microbiol. 2018;8:398. doi: 10.3389/fcimb.2018.00398.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2018.00398</ArticleId><ArticleId IdType="pmc">PMC6240593</ArticleId><ArticleId IdType="pubmed">30483483</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekerman E., Neveu G., Shulla A., Brannan J., Pu S.Y., Wang S., Xiao F., Barouch-Bentov R., Bakken R.R., Mateo R., et al. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J. Clin. Investig. 2017;127:1338&#x2013;1352. doi: 10.1172/JCI89857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI89857</ArticleId><ArticleId IdType="pmc">PMC5373883</ArticleId><ArticleId IdType="pubmed">28240606</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu J.J., Yang P.L. C-src protein kinase inhibitors block assembly and maturation of dengue virus. Proc. Natl. Acad. Sci. USA. 2007;104:3520&#x2013;3525. doi: 10.1073/pnas.0611681104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0611681104</ArticleId><ArticleId IdType="pmc">PMC1805510</ArticleId><ArticleId IdType="pubmed">17360676</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdallah S.M., Hirsh V. Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in egfr activating mutation-positive advanced non-small-cell lung cancer. Curr. Oncol. 2018;25:S9&#x2013;S17. doi: 10.3747/co.25.3732.</Citation><ArticleIdList><ArticleId IdType="doi">10.3747/co.25.3732</ArticleId><ArticleId IdType="pmc">PMC6001770</ArticleId><ArticleId IdType="pubmed">29910643</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsh V. Next-generation covalent irreversible kinase inhibitors in nsclc: Focus on afatinib. BioDrugs Clin. Immunothe. Biopharm. Gene Ther. 2015;29:167&#x2013;183. doi: 10.1007/s40259-015-0130-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-015-0130-9</ArticleId><ArticleId IdType="pmc">PMC4488453</ArticleId><ArticleId IdType="pubmed">26123538</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y., Gao X., Maragh S., Telford W.G., Tona A. Cell lines as candidate reference materials for quality control of erbb2 amplification and expression assays in breast cancer. Clin. Chem. 2009;55:1307&#x2013;1315. doi: 10.1373/clinchem.2008.120576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2008.120576</ArticleId><ArticleId IdType="pubmed">19443566</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z., Hackshaw A., Feng Q., Fu X., Zhang Y., Mao C., Tang J. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis. Int. J. Cancer. 2017;140:2805&#x2013;2819. doi: 10.1002/ijc.30691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.30691</ArticleId><ArticleId IdType="pubmed">28295308</ArticleId></ArticleIdList></Reference><Reference><Citation>Samanta J., Sharma V. Dengue and its effects on liver. World J. Clin. Cases. 2015;3:125&#x2013;131. doi: 10.12998/wjcc.v3.i2.125.</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v3.i2.125</ArticleId><ArticleId IdType="pmc">PMC4317605</ArticleId><ArticleId IdType="pubmed">25685758</ArticleId></ArticleIdList></Reference><Reference><Citation>Thepparit C., Khakpoor A., Khongwichit S., Wikan N., Fongsaran C., Chingsuwanrote P., Panraksa P., Smith D.R. Dengue 2 infection of hepg2 liver cells results in endoplasmic reticulum stress and induction of multiple pathways of cell death. BMC Res. Notes. 2013;6:372. doi: 10.1186/1756-0500-6-372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-0500-6-372</ArticleId><ArticleId IdType="pmc">PMC3847886</ArticleId><ArticleId IdType="pubmed">24034452</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.L., Liu C.C., Lei H.Y., Yeh T.M., Lin Y.S., Chen R.M., Liu H.S. Infection of five human liver cell lines by dengue-2 virus. J. Med. Virol. 2000;60:425&#x2013;431. doi: 10.1002/(SICI)1096-9071(200004)60:4&lt;425::AID-JMV10&gt;3.0.CO;2-A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9071(200004)60:4&lt;425::AID-JMV10&gt;3.0.CO;2-A</ArticleId><ArticleId IdType="pubmed">10686026</ArticleId></ArticleIdList></Reference><Reference><Citation>Pu S.Y., Xiao F., Schor S., Bekerman E., Zanini F., Barouch-Bentov R., Nagamine C.M., Einav S. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. Antivir. Res. 2018;155:67&#x2013;75. doi: 10.1016/j.antiviral.2018.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2018.05.001</ArticleId><ArticleId IdType="pmc">PMC6064211</ArticleId><ArticleId IdType="pubmed">29753658</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Xu B. Targeted therapeutic options and future perspectives for her2-positive breast cancer. Signal. Trans. Target. Ther. 2019;4:34. doi: 10.1038/s41392-019-0069-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-019-0069-2</ArticleId><ArticleId IdType="pmc">PMC6799843</ArticleId><ArticleId IdType="pubmed">31637013</ArticleId></ArticleIdList></Reference><Reference><Citation>Gingras I., Gebhart G., de Azambuja E., Piccart-Gebhart M. Her2-positive breast cancer is lost in translation: Time for patient-centered research. Nat. Rev. Clin.l Oncol. 2017;14:669&#x2013;681. doi: 10.1038/nrclinonc.2017.96.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrclinonc.2017.96</ArticleId><ArticleId IdType="pubmed">28762384</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu T., Claret F.X. Trastuzumab: Updated mechanisms of action and resistance in breast cancer. Front. Oncol. 2012;2:62. doi: 10.3389/fonc.2012.00062.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2012.00062</ArticleId><ArticleId IdType="pmc">PMC3376449</ArticleId><ArticleId IdType="pubmed">22720269</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y.J., Higgs S., Horne K.M., Vanlandingham D.L. Flavivirus-mosquito interactions. Viruses. 2014;6:4703&#x2013;4730. doi: 10.3390/v6114703.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v6114703</ArticleId><ArticleId IdType="pmc">PMC4246245</ArticleId><ArticleId IdType="pubmed">25421894</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., Drake J.M., Brownstein J.S., Hoen A.G., Sankoh O., et al. The global distribution and burden of dengue. Nature. 2013;496:504&#x2013;507. doi: 10.1038/nature12060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12060</ArticleId><ArticleId IdType="pmc">PMC3651993</ArticleId><ArticleId IdType="pubmed">23563266</ArticleId></ArticleIdList></Reference><Reference><Citation>Estofolete C.F., Terzian A.C.B., Colombo T.E., de Freitas Guimaraes G., Ferraz H.C.J., da Silva R.A., Greque G.V., Nogueira M.L. Co-infection between zika and different dengue serotypes during denv outbreak in brazil. J. Infect. Public Health. 2019;12:178&#x2013;181. doi: 10.1016/j.jiph.2018.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2018.09.007</ArticleId><ArticleId IdType="pubmed">30301701</ArticleId></ArticleIdList></Reference><Reference><Citation>Laredo-Tiscareno S.V., Garza-Hernandez J.A., Salazar M.I., De Luna-Santillana E.J., Tangudu C.S., Cetina-Trejo R.C., Doria-Cobos G.L., Carmona-Aguirre S.D., Garcia-Rejon J.E., Machain-Williams C., et al. Surveillance for flaviviruses near the mexico-u.S. Border: Co-circulation of dengue virus serotypes 1, 2, and 3 and west nile virus in tamaulipas, northern mexico, 2014&#x2013;2016. Am. J. Trop. Med. Hyg. 2018;99:1308&#x2013;1317. doi: 10.4269/ajtmh.18-0426.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.18-0426</ArticleId><ArticleId IdType="pmc">PMC6221250</ArticleId><ArticleId IdType="pubmed">30226141</ArticleId></ArticleIdList></Reference><Reference><Citation>Behnam M.A., Nitsche C., Boldescu V., Klein C.D. The medicinal chemistry of dengue virus. J. Med. Chem. 2016;59:5622&#x2013;5649. doi: 10.1021/acs.jmedchem.5b01653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.5b01653</ArticleId><ArticleId IdType="pubmed">26771861</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Shachar R., Schmidler S., Koelle K. Drivers of inter-individual variation in dengue viral load dynamics. PLoS Comput.Biol. 2016;12:e1005194. doi: 10.1371/journal.pcbi.1005194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1005194</ArticleId><ArticleId IdType="pmc">PMC5113863</ArticleId><ArticleId IdType="pubmed">27855153</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein D.A., Perry S.T., Buck M.D., Oehmen C.S., Fischer M.A., Poore E., Smith J.L., Lancaster A.M., Hirsch A.J., Slifka M.K., et al. Inhibition of dengue virus infections in cell cultures and in ag129 mice by a small interfering rna targeting a highly conserved sequence. J. Virol. 2011;85:10154&#x2013;10166. doi: 10.1128/JVI.05298-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.05298-11</ArticleId><ArticleId IdType="pmc">PMC3196423</ArticleId><ArticleId IdType="pubmed">21795337</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreekanth G.P., Chuncharunee A., Sirimontaporn A., Panaampon J., Srisawat C., Morchang A., Malakar S., Thuwajit P., Kooptiwut S., Suttitheptumrong A., et al. Role of erk1/2 signaling in dengue virus-induced liver injury. Virus Res. 2014;188:15&#x2013;26. doi: 10.1016/j.virusres.2014.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2014.03.025</ArticleId><ArticleId IdType="pubmed">24704674</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C.Y., Pan C.H., Hsieh C.H., Tsai J.P., Chen M.Y., Liu H.H., Liu S.J., Chong P., Leng C.H., Chen H.W. Lipidated dengue-2 envelope protein domain iii independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement. PLoS Negle. Trop. Dis. 2013;7:e2432. doi: 10.1371/journal.pntd.0002432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002432</ArticleId><ArticleId IdType="pmc">PMC3777875</ArticleId><ArticleId IdType="pubmed">24069487</ArticleId></ArticleIdList></Reference><Reference><Citation>Simanjuntak Y., Liang J.J., Chen S.Y., Li J.K., Lee Y.L., Wu H.C., Lin Y.L. Ebselen alleviates testicular pathology in mice with zika virus infection and prevents its sexual transmission. PLoS Pathog. 2018;14:e1006854. doi: 10.1371/journal.ppat.1006854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006854</ArticleId><ArticleId IdType="pmc">PMC5814061</ArticleId><ArticleId IdType="pubmed">29447264</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh M.S., Chen M.Y., Hsieh C.H., Pan C.H., Yu G.Y., Chen H.W. Detection and quantification of dengue virus using a novel biosensor system based on dengue ns3 protease activity. PLoS ONE. 2017;12:e0188170. doi: 10.1371/journal.pone.0188170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0188170</ArticleId><ArticleId IdType="pmc">PMC5697845</ArticleId><ArticleId IdType="pubmed">29161301</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>